ReviewLa Radiologia medica2026
PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.
Review in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Accurately assessing tumor response to immunotherapy remains a significant clinical challenge due to the unique response patterns and limitations of conventional anatomical imaging. This review explores the evolving application of PET/CT in evaluating immunotherapy efficacy through the novel lens of tumor metabolic reprogramming and immune escape mechanisms. First, we examine how metabolic imbalances in the tumor microenvironment mediate immune escape by suppressing immune cell function. The review subsequently analyzes advances in molecular imaging, focusing on the development of novel radiopharmaceuticals that target specific immunometabolism pathways, enabling direct visualization of immune cell dynamics. Furthermore, we analyze advances in novel tracers targeting specific immunometabolism processes for direct immune cell visualization, along with the application of radiomics for early response prediction. Finally, we address current technical and clinical challenges, outlining future directions aimed at constructing an integrated tumor metabolic-immune map and developing robust, PET-based patient stratification strategies to guide personalized therapeutic regimens. In conclusion, PET/CT is emerging as an indispensable multi-dimensional tool, providing critical real-time insights into immunometabolism activity to optimize therapeutic decision-making and improve clinical outcomes in cancer immunotherapy. Integrating these metabolic-immune signatures with other biomarker data holds promise for refining response assessment strategy and advancing personalized oncology.
Indexed as
Identifiers
42550459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.